Orexo AB Enters An Exclusive Reimbursement Agreement With Unitedhealth Group And Optumrx For ZUBSOLV®

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO:ORX), the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC